Adhera Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adhera Therapeutics, Inc.
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.
The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics.
Accord Healthcare has launched an app to support cancer patients and help manage symptoms, incorporating expert data from Macmillan Cancer Support.
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Cequent Pharmaceuticals
- IthenaPharma Inc.
- Marina Biotech, Inc.
- MDRNA, Inc.
- Nastech Pharmaceutical Company Inc.